Shots:

• The approval is based on P-III ADAURA trial assessing Tagrisso (80mg- qd- PO) vs PBO in 682 patients with stage IB- II- IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3 yrs. or until disease recurrence
• Results: Improvement in DFS in all primary analysis population in Stage II and IIIA EGFRm NSCLC patients and overall trial population- 83% reduction in the risk of disease recurrence or death- and 80% reduction in the overall trial population in patients with Stage IB-IIIA disease
• Tagrisso is an approved therapy for 1L LA or mEGFRm NSCLC and for LA or mEGFR T790M mutation+ NSCLC in the EU- the US- Japan- China and many other countries

  Ref: AstraZeneca | Image: New Europe